An Observational Clinical Study Investigating the Immune Response, Safety and Survival of the TG01/GM-CSF Vaccine in Treatment Naive Non-Resectable Pancreatic Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
Price : $35 *
At a glance
- Drugs TG 01 Targovax (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.